KRAS Mutation Predicts Pembrolizumab Response in NSCLC KRAS Mutation Predicts Pembrolizumab Response in NSCLC

A new study, published as a preprint, reported a better way to predict if patients with metastatic nonsmall cell lung cancer will respond to pembrolizumab.First Look
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news